New follow-up study shows that a naturally occurring coenzyme nutritional supplement Enada® NADH clinically demonstrates benefits for Alzheimer’s patients

Vienna, Austria (11/02) – At the 2nd International Conference on Mechanisms and Actions of Nutraceuticals (ICMAN) the findings of a study conducted by an international team of medical researchers under the direction of Professor V. Demarin, MD, Ph.D. of Sestre milosrdnice University Hospital confirmed the use of ENADA® NADH as a treatment for Alzheimer’s disease. In this double blind, placebo controlled, matched pairs, clinical study after 6 months of treatment, the subjects treated with NADH (10mg/day) showed no evidence of progressive cognitive deterioration and had significantly higher total scores on the Mattis Dementia Rating Scale (MDRS) compared to subjects treated with placebo (p<.05). Also, no side effects have been observed in any of the patients.

ICMAN Nov-19, 2002 Studyon Alzheimers

ENADA NADH Improves Cognitive Impairment

Treatmentof Alzheimers Double Blind Study October-2002